Evidence map›Paper›PMID 38326914›Full record

ArticleChemMedChem2024

Tractable Quinolone Hydrazides Exhibiting Sub-Micromolar and Broad Spectrum Antitrypanosomal Activities.

Kgothatso A Chirwa, Karol R Francisco, Phelelisiwe S Dube, Hayoung Park, Lesetja J Legoabe, Thaiz Rodrigues Teixeira, Conor R Caffrey, Richard M Beteck

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ChemMedChem, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Kgothatso A ChirwaCentre of Excellence for Pharmaceutical Sciences, North-West University, Potchefstroom, 2520, South Africa.
Karol R FranciscoCenter for Discovery and Innovation in Parasitic Diseases, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA.
Phelelisiwe S DubeCentre of Excellence for Pharmaceutical Sciences, North-West University, Potchefstroom, 2520, South Africa.
Hayoung ParkCenter for Discovery and Innovation in Parasitic Diseases, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA.
Lesetja J LegoabeCentre of Excellence for Pharmaceutical Sciences, North-West University, Potchefstroom, 2520, South Africa.
Thaiz Rodrigues TeixeiraCenter for Discovery and Innovation in Parasitic Diseases, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA.
Conor R CaffreyCenter for Discovery and Innovation in Parasitic Diseases, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA.
Richard M BeteckCentre of Excellence for Pharmaceutical Sciences, North-West University, Potchefstroom, 2520, South Africa.ORCID 0000-0002-6282-043X

Funding

RESEARCH IN INFECTIOUS DISEASEST32AI007036 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI NIZET, VICTOR · 1985 to 2025
$9.2M
The catalytic core of the proteasome as a drug target to treat Human African TrypanosomiasisR21AI171824 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CAFFREY, CONOR, O'DONOGHUE, ANTHONY JOHN · 2022 to 2023
$435k
NIAID NIH HHS R21 AI171824NIAID NIH HHS T32 AI007036
6 · The paper itself

Abstract

Nagana and Human African Trypanosomiasis (HAT), caused by (sub)species of Trypanosoma, are diseases that impede human and animal health, and economic growth in Africa. The few drugs available have drawbacks including suboptimal efficacy, adverse effects, drug resistance, and difficult routes of administration. New drugs are needed. A series of 20 novel quinolone compounds with affordable synthetic routes was made and evaluated in vitro against Trypanosoma brucei and HEK293 cells. Of the 20 compounds, 12 had sub-micromolar potencies against the parasite (EC

Indexed as

Parasitic Sensitivity TestsQuinolonesTrypanocidal AgentsTrypanosoma brucei bruceiDose-Response Relationship, DrugHEK293 CellsHumansHydrazinesMolecular StructureStructure-Activity RelationshipTrypanosoma cruziHydrazinesQuinolonesTrypanocidal AgentsDrugHydrazideNaganaQuinoloneTrypanosomiasis

Identifiers

PMID38326914
PMCPMC11076157

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.